Drug name is Contenidos
A novel method of drug delivery developed by a Welsh University, is based on the principal that the expression of biologically active molecules as fusion proteins with antibody Fc substantially extends the plasma half life of an active agent and may influence function. The hybrid molecule has a longer plasma half life with a reduced biological activity. This loss of function may remove the unwanted side effects of the therapeutic agent provided that release at target site could be achieved. Because systematic inhibition of complement is a major problem with current anti-complement drugs, a Fc fusion protein based pro-drug with low complement regulatory activity that could be cleaved at sites of inflammation to release active regulator was engineered as proof of concept.
Innovative Aspects:
Two "model" pro-drugs which have a decrease or absence of complement inhihitory activity when compared to the parent regulator in vitro, have been developed. Exposure of the pro-drugs to the relevant enzymes, either as pure enzyme in vitro or generated in situ in an ex vivo model of tissue inflammation, efficiently cleaved the pro-drug, releasing the active regulator. The method has the potential to be used in multiple applications and future treatments of inflammatory diseases.
Main Advantages:
These novel agents represent a paradigm for the next generation of anti-complement therapeutics. The pro-drug concept has many applications such as targeting various protein therapeutics, ranging from cytokines and anti-cytokines through to cytotoxic agents, limiting the systemic effects of the agents and maximising delivery of active drug to the site of pathology. The novel method for drug delivery may aid in the development of treatments for RA as it incorporates crucial information on the complement system and how it can be manipulated and controlled. Such information is crucial to the understanding of the immune system and to the development of future treatments for inflammatory disorders.